Drug updated on 12/11/2024
| Dosage Form | Tablet (oral: 250 mg) |
| Drug Class | Tryptophan hydroxylase Inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.
Latest News
Summary
- This summary is based on the review of one systematic review/meta-analysis. [1]
- The study does not provide specific effectiveness data for telotristat ethyl (Xermelo) in treating carcinoid syndrome (CS) but highlights economic and quality-of-life impacts for patients with neuroendocrine tumors and CS.
- Patients with uncontrolled CS symptoms experienced 23-92% higher costs compared to those with controlled symptoms, with ambulatory/outpatient services being the main cost driver.
- Quality of life (QOL) is notably impaired in patients with CS, although the study does not detail how different population types or subgroups were affected by telotristat ethyl.
- There is no safety information available in the reviewed studies.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Xermelo (telotristat ethyl) Prescribing Information. | 2022 | Lexicon Pharmaceuticals, Inc., The Woodlands, TX |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome | 2021 | PharmacoEconomics |